Skip to content
Saturday 29 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Tuesday 16 June 2020 1:29 pm  |  Updated:  Tuesday 16 June 2020 3:28 pm

UK scientists make ‘major breakthrough’ as common steroid found to cut coronavirus death rate

By: Edward Thicknesse

Add as a preferred source on Google
A common steroid has been labelled a "major breakthrough" in the fight against coronavirus by researchers

A common steroid has been labelled a “major breakthrough” in the fight against coronavirus by researchers after trials showed it cut the risk of death for those patients on ventilators by a third.

The drug, which is called dexamethasone, is widely available, and scientists said it would be “instantly affordable” worldwide.

The results of the trial showed that the drug reduced the death rate of those on ventilators from 41 per cent to 28 per cent, and of those requiring oxygen from 25 per cent to 20 per cent.

Based on the results, for every 8 ventilated patients treated with the drug one life would be saved.

Likewise, one in every 25 patients requiring oxygen would be survive through the use of the drug alone.

England’s chief medical officer Chris Whitty said the findings were “the most important trial result” for the disease so far.

The Recovery trial was carried out by scientists at the University of Oxford and involved a total of 2104 patients.

Professor Peter Horby, one of the trial’s chief investigators, said that the drug should now become the “standard care” for those sick enough to need oxygen.

He said: “Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result.

Read more

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

“The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients.

“Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide”.

Fellow chief investigator Professor Martin Landray agreed, saying it was “fantastic that the first treatment demonstrated to reduce mortality is one that is instantly available and affordable worldwide”.

The scientists said that the full results of the trial would be made available as soon as possible.

Nick Cammack of the Welcome Trust called the results of the trial “remarkable”.

“Potentially preventing 1 death in every 8 ventilated patients would be remarkable”, he said. 

“Finding effective treatments like this will transform the impact of the Covid-19 pandemic on lives and economies across the world.

Read more

Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Related Topics

  • Coronavirus
  • International

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • As it happened: FTSE 100 falls but Nasdaq soars after Nvidia sales boom

More from Morning Wire

  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • Harvey Nichols will collapse without rescue deal, directors warn

    Retail
    Exterior view of the Harvey Nichols luxury department store building facade with prominent black lettering and ornate arch...
  • U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

    Business Wire
  • Moove Raises $250 Million at $2.1 Billion Valuation to Scale the Global Infrastructure Layer for Autonomous Mobility

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook